KR20180082791A - Micro-needles, mamufacture apparatus thereof and method of mamufacture using them - Google Patents

Abstract

A microneedle manufacturing apparatus for manufacturing a microneedle coated with a drug solution according to the disclosed present invention comprises: a supporting unit for supporting a drug solution for coating a microneedle; and a control unit for controlling a temperature of the drug solution carried on the supporting unit, wherein the control unit keeps the temperature of the drug solution at a constant temperature by cooling. According to the configuration, the quality of the microneedle coated with the drug solution can be enhanced by controlling the temperature of the drug solution so that an appropriate viscosity for the drug solution coating is maintained.

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention [0001] The present invention relates to a microneedle, a microneedle, a manufacturing method thereof, and a microneedle manufacturing method using the microneedle,

The present invention relates to a microneedle, an apparatus for producing the microneedle, and a method of manufacturing a microneedle using the microneedle. More particularly, the present invention relates to a microneedle capable of improving the quality by controlling the viscosity of the microneedle, And a microneedle manufacturing method using the same.

The transdermal drug delivery system has a limitation in the size of the drug solution molecular weight that can be delivered. Therefore, various active transdermal drug delivery systems have recently been proposed. Among them, the micro needle method, which passes the keratin and directly administers the drug solution to the skin layer, is receiving the most attention. The microneedles are made by drilling fine holes in the stratum corneum surface of the outermost layer and then delivering the drug, and the length of the needle can be varied to 90 to 1500 μm according to the purpose of drug delivery.

Coated micro needles, which are one of the types of micro needles, have a merit in that the process is simple and the production cost is economical because the composition containing the drug to be delivered is coated on the surface of the micro needle and delivered to the skin layer. On the other hand, in such coated micro-needles, viscosity control is difficult due to progress of coating process at room temperature and denaturation of active ingredient occurs at room temperature. Accordingly, in recent years, various studies have been continuously carried out to improve the dosage by easily controlling the viscosity of the micro needle.

Korean Patent Publication No. 2014-0006167 Japanese Patent No. 4750347

SUMMARY OF THE INVENTION It is an object of the present invention to provide a microneedle capable of coating a uniform liquid through viscosity control, an apparatus for manufacturing the same, and a method of manufacturing a microneedle using the same.

According to another aspect of the present invention, there is provided a micro needle manufacturing apparatus for manufacturing a micro needle coated with a drug solution. The micro needle manufacturing apparatus includes a holding unit carrying a drug solution for coating the micro needle, And the control unit controls the temperature of the chemical liquid to be maintained at a predetermined temperature by cooling the temperature of the chemical liquid.

According to one aspect of the present invention, the carrying unit has a container shape with an open top, and the adjusting unit is provided at the bottom of the carrying unit to cool the temperature of the carrying unit.

According to one aspect of the present invention, the control unit includes a temperature holding member provided at the bottom of the supporting unit to maintain the temperature of the chemical solution, and a cooling unit provided at the bottom of the supporting unit with the temperature holding member interposed therebetween, And a cooling member.

According to one aspect, the temperature holding member includes a Peltier element, and the cooling member may include a cooling fan for cooling by the coolant.

According to a preferred embodiment of the present invention, there is provided a method of manufacturing a microneedle, comprising: adjusting a temperature of a chemical solution; and supporting the micro-needle with the chemical solution to coat the surface of the micro-needle with the chemical solution, The step is to cool and maintain the temperature of the chemical liquid.

According to one aspect of the present invention, in the chemical liquid adjusting step, the chemical liquid supported on the supporting unit is cooled through the cooling member, and then the chemical liquid holding member including the Peltier element can maintain the temperature of the chemical liquid at a predetermined temperature.

According to one aspect, after the chemical liquid coating step, drying may be performed by drying the micro-needle coated with the chemical liquid.

According to one aspect, the drug solution may be formed by mixing a biocompatible material with a solvent.

According to one aspect, the biocompatible material is selected from the group consisting of hyaluronic acid, alginic acid, pectin, carrageenan, chondroitin (sulfate), dextran (sulfate), chitosan, polylysine, (PGA), polylactide-glycolidide copolymer (PLGA), hyaluronic acid (PEG), polyglycolide (PEG) Alginic acid, carrageenan, chondroitin (sulfate), dextran (sulfate), chitosan, polylysine, collagen, gelatin, carboxymethyl chitin, fibrin, agarose, Polyanhydride, polyorthoester, polyetherester, polycaprolactone, polyesteramide, poly (butyric acid), poly (ethylene glycol) Polyacrylic acid, ethylene-vinyl acetate polymer, acrylic substituted cellulose acetate, non-degradable polyurethane, polystyrene, polyvinyl chloride, polyvinyl fluoride, poly (vinylimidazole), chlorosulfonate Polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), polymethacrylate, hydroxypropylmethylcellulose (HPMC), ethylcellulose (EC), hydroxypropylcellulose (HPC), polyvinylpyrrolidone ), Carboxymethylcellulose, cyclodextrin, and copolymers of monomers forming such a polymer and cellulose.

According to one aspect, the chemical liquid is mixed with an additive for increasing the mechanical strength, and the additive is selected from the group consisting of trehalose, glucose, maltose, lactose, lactulose, fructose, turanose, melitose, melitose, dextran, sorbitol, Poly (lactide-co-glycolide), polyanhydride, polyorthoester, poly (lactide-co-glycolide), poly But are not limited to, polyether sulfone, polyetheretherketone, polyetherester, polycaprolactone e, polyesteramide, poly (butyric acid), poly (valeric acid), polyurethane, polyacrylate, ethylene- Cellulose acetate, non-degradable polyurethane, polystyrene, polyvinyl chloride, polyvinyl fluoride, poly (vinyl imidazole), chlorosulfonate, (HPC), ethylcellulose (EC), hydroxypropylcellulose (HPC), polyvinylpyrrolidone (PVP), polyethyleneglycol (PEG), polymethacrylate, hydroxypropylmethylcellulose , Carboxymethylcellulose, cyclodextrin, and copolymers of monomers that form such a polymer.

According to one aspect, the drug solution is mixed with an active ingredient and the active ingredient is selected from the group consisting of a protein / peptide drug, a hormone, a hormone analog, an enzyme, an enzyme inhibitor, a signal transduction protein or a part thereof, an antibody or a part thereof, Binding domain, an antigen, an attachment protein, a structural protein, a regulatory protein, a toxin protein, a cytokine, a transcription regulator, a blood coagulation factor and a vaccine.

According to one aspect, the protein / peptide medicament is selected from the group consisting of insulin, IGF-1 (insulin sensitization factor 1), growth hormone, erythropoietin, granulocyte-colony stimulating factors (G-CSFs), granulocyte / macrophage- stimulating factors, interferon alpha, interferon beta, interferon gamma, interleukin-1 alpha and beta, interleukin-3, interleukin-4, interleukin-6, interleukin-2, epidermal growth factors, calcitonin, The compounds of the present invention may be used in combination with other therapeutic agents such as ACTH (adrenocorticotropic hormone), TNF (tumor necrosis factor), atobisban, buserelin, cetrorelix, deslorelin, desmopressin, Dynorphin A (1-13), elcatonin, eleidosin, eptifibatide, growth hormone releasing hormone-II (GHRH-II), gonadolerin gonadorelin, goserelin, histrelin, leuprorelin, lypressin, , Octreotide, oxytocin, pitressin, secretin, sincalide, terlipressin, thymopentin, thymosine, thymocyte, The compounds of the present invention may be used in combination with other drugs such as triptorelin, bivalirudin, carbetocin, cyclosporine, exedine, lanreotide, luteinizing hormone-releasing hormone (LHRH) nafarelin, parathyroid hormone, pramlintide, T-20 (enfuvirtide), thymalfasin and chicotanide.

According to one aspect, the chemical solution is added with a solvent, and the solvent is selected from the group consisting of DI water, methanol, ethanol, chloroform dibutyl phthalate, dimethyl phthalate, an organic solvent such as ethanol, ethanol, isopropyl alcohol, phthalate, ethyl lactate, glycerin, isopropyl alcohol, lactic acid, propylene glycol and the like.

The microneedle according to a preferred embodiment of the present invention includes a step of adjusting the temperature of the chemical liquid and a step of coating the chemical liquid on the surface of the micro needle by supporting the micro needle with the chemical liquid, And the temperature of the chemical liquid is cooled and maintained.

According to the present invention having the above-described structure, first, by adjusting the temperature of the chemical liquid for coating the micro needle, it is possible to control the viscosity to a suitable value for coating. As a result, the chemical liquid can be uniformly spread to the support unit, thereby improving the coating quality of the micro needle.

Second, by controlling the temperature of the chemical liquid, it is possible to suppress the denaturation of the chemical liquid and the evaporation of the solvent, thereby increasing the drug content at the time of coating.

Third, the viscosity can be easily controlled by adjusting the temperature, instead of adding the thickener, which is an excipient, to the drug solution in an excessive amount, so that the content of the drug solution coated on the micro needle can be increased.

1 is a perspective view schematically showing a microneedle manufacturing apparatus according to a preferred embodiment of the present invention.
FIG. 2 is a perspective view schematically showing microneedles fabricated by the microneedle manufacturing apparatus shown in FIG. 1. FIG.
3 is a flowchart schematically illustrating a method of manufacturing a micro needle using the micro needle manufacturing apparatus shown in FIG.
4 is a graph schematically showing a viscosity change of a chemical liquid with a change in temperature.
5 is a graph schematically showing the evaporation rate of the chemical liquid at different temperatures from each other under the same viscous condition.
FIG. 6 shows images obtained by photographing micro-needles coated with three drug solutions having different temperature and viscosity conditions by optical microscope and comparing their surface coating states. And,
FIG. 7 is an image obtained by photographing an increased amount of the surface coated amount of the micro needle according to an increase in viscosity with an optical microscope.

Hereinafter, a preferred embodiment of the present invention will be described with reference to the accompanying drawings.

Referring to FIG. 1, a microneedle manufacturing apparatus 10 according to a preferred embodiment of the present invention includes a carrying unit 20 and a regulating unit 30.

For reference, the microneedle manufacturing apparatus 10 described in this embodiment is exemplified as a device for manufacturing the coated microneedle 1 coated with the chemical liquid M penetrating into the inside of the skin.

The carrying unit 20 carries a chemical liquid M for coating the micro needles 1. The loading unit 20 has the same shape as the container with the top opened, and the chemical liquid M is carried. 1, the top of the loading unit 20 is opened and illustrated, but the present invention is not limited thereto. That is, a modified example is possible in which the upper portion of the carrying unit 20 is selectively opened and closed by the cover.

The control unit (30) regulates the temperature of the chemical liquid (M) carried on the carrying unit (20). The regulating unit 30 includes cooling means for cooling the temperature of the chemical liquid M, thereby regulating the temperature of the chemical liquid M. [ To this end, the regulating unit 30 includes a temperature holding member 31 and a cooling member 32.

The temperature holding member 31 is provided at the bottom of the holding unit 20 to maintain the temperature of the chemical liquid M. [ This temperature holding member 31 is exemplified as including a Peltier effect device in the present embodiment. That is, the temperature holding member 31 includes a Peltier element, which is an electronic cooling element, so that the temperature of the holding unit 20 is cooled and maintained by using the Peltier effect that one side generates heat while the other side absorbs heat.

The cooling member 32 is provided at the bottom of the carrying unit 20 with the temperature holding member 31 interposed therebetween to cool the temperature holding member 31 including the Peltier element for cooling the temperature of the carrying unit 20 Cool the heat generated during the process. The cooling member 32 includes a cooling fan connected to the refrigerant source 33 to cool the chemical liquid M carried on the loading unit 20. [

Although not shown in detail, the refrigerant source 33 of the cooling member 32 is connected to the refrigerant storage unit and the refrigerant storage unit to store a space for storing the refrigerant, And a cover part connected to the refrigerant storage part to discharge the refrigerant from the refrigerant storage part to the outside, and a cover part coupled to the refrigerant injection part and the refrigerant discharge part to prevent the refrigerant from flowing out.

The adjustment unit 30 having the above configuration can cool the temperature of the chemical liquid M carried on the loading unit 20 to a desired temperature, for example, 4 to 15 DEG C, to maintain the viscosity suitable for the coating. That is, by lowering the temperature of the chemical liquid M, a viscosity region can be formed in which the chemical liquid M can be uniformly coated on the surface of the micro needle 1 even with a small amount of thickener.

Referring to Fig. 2, a micro needle 1 manufactured by the micro needle manufacturing apparatus 10 shown in Fig. 1 is shown. 2, the micro needles 1 are provided with a plurality of tips 3 on a base 2 and coated with a chemical solution M on a plurality of tips 3.

More specifically, the tip (3) includes a tip (3) coated with a drug solution (M) penetrating and melting the skin. The tip (3) has a sharp end shape to facilitate penetration of the skin (S). In this embodiment, the tip 3 is illustrated as having a substantially conical shape, but is not limited thereto. In addition, the number of the tips 3 is not limited to the illustrated example.

The base (2) supports a plurality of tips (3). That is, the base 2 is the body of the microneedle 1 which simultaneously supports the plurality of tips 3.

1, the micro needle 1 is supported on the drug solution M of the holding unit 20 for a certain period of time and then ascended or descended. As a result, as shown in FIG. 2, (1) is produced. A manufacturing method of such a micro needle 1 is summarized in FIG.

3, the method of manufacturing the micro needle 1 includes a step 100 of adjusting the temperature of the chemical liquid M and a step 200 of coating the chemical liquid M. [

The temperature adjusting step 100 of the chemical solution M cools the temperature of the chemical solution M carried on the loading unit 20 to a desired temperature and keeps the conditioning unit 30 cooling the same. Thus, when the temperature of the chemical liquid M is adjusted, the chemical liquid M can maintain an appropriate viscosity for the coating.

The microneedle 1 is supported by the temperature-controlled drug solution M so that the drug solution M is coated on the tip 3 (200). The micro needle 1 coated with the chemical solution M is finally manufactured through a drying step 300 in which the micro-needle 1 is dried off the carrying unit 20.

For reference, the chemical solution (M) described in the present invention is a mixed solution in which a biocompatible substance is mixed with a solvent. In this embodiment, the drug solution M is a 1% aqueous solution of a polymer in which a biocompatible material containing 0.01 g of hyaluronic acid is dissolved in a solvent containing 1 ml of purified water (DW) .

Wherein the biocompatible material is selected from the group consisting of hyaluronic acid, alginic acid, pectin, carrageenan, chondroitin (sulfate), dextran (sulfate), chitosan, polylysine, collagen, gelatin Carboxymethyl chitin, fibrin, agarose, pullulan polylactide, polyglycolide (PGA), polylactide-glycolidide copolymer (PLGA), hyaluronic acid, (S) selected from the group consisting of alginic acid, carrageenan, chondroitin (sulfate), dextran (sulfate), chitosan, polylysine, collagen, gelatin, carboxymethyl chitin, fibrin, agarose, pullulan polyanhydride polyanhydride, polyorthoester, polyetherester, polycaprolactone, polyesteramide, poly (butyric acid), poly (valeric acid) ), Polyurethane, polyacrylate, ethylene-vinyl acetate polymer, acrylic substituted cellulose acetate, non-degradable polyurethane, polystyrene, polyvinyl chloride, polyvinyl fluoride, poly (vinylimidazole), chlorosulfonate polyolefin chlorosulphonate polyolefins, polyethylene oxide, polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), polymethacrylate, hydroxypropylmethylcellulose (HPMC), ethylcellulose (EC), hydroxypropylcellulose (HPC) Carboxymethylcellulose, cyclodextrin, and copolymers of monomers forming such a polymer and cellulose.

Further, the chemical liquid (M) is formed by mixing a biocompatible material and an additive for increasing the mechanical strength. The additive may be selected from the group consisting of trehalose, glucose, maltose, lactose, lactulose, fructose, turanose, melitose, melitose, dextran, sorbitol, xylitol, palatinite, mannitol, poly (Glycolides), poly (lactide-co-glycolide), polyanhydride, polyorthoester, polyetherester, polycaprolactone e, but are not limited to, polyesteramide, poly (butyric acid), poly (valeric acid), polyurethanes, polyacrylates, ethylene-vinyl acetate polymers, acrylic substituted cellulose acetate, non-degradable polyurethanes, polystyrene, polyvinyl chloride, Poly (vinylimidazole), chlorosulfonate, chlorosulphonate polyolefins, polyethylene oxide, polyvinylpyrrolidone (PVP), poly (PEG), polymethacrylate, hydroxypropylmethylcellulose (HPMC), ethylcellulose (EC), hydroxypropylcellulose (HPC), carboxymethylcellulose, cyclodextrin, and monomers forming these polymers Or a combination of two or more substances selected from the group consisting of.

Further, the chemical liquid (M) is formed by mixing a biocompatible material with an active ingredient. Such active ingredients include, but are not limited to, protein / peptide drugs, hormones, hormone analogs, enzymes, enzyme inhibitors, signaling proteins or parts thereof, antibodies or portions thereof, single chain antibodies, binding proteins or binding domains thereof, , Adhesion protein, structural protein, regulatory protein, toxin protein, cytokine, transcription regulator, blood coagulation factor and vaccine. More specifically, the protein / peptide medicament may be selected from the group consisting of insulin, insulin sensitization factor 1 (IGF-1), growth hormone, erythropoietin, granulocyte-colony stimulating factors (G-CSFs), granulocyte / macrophage- interleukin-1, interleukin-2, EGFs (epidermal growth factors), calcitonin, interleukin-1, interleukin- , Adrenocorticotropic hormone (ACTH), tumor necrosis factor (TNF), atobisban, buserelin, cetrorelix, deslorelin, desmopressin, , Dynorphin A (1-13), elcatonin, eleidosin, eptifibatide, growth hormone releasing hormone-II (GHRH-II), konadorerin gonadorelin, goserelin, histrelin, leuprorelin, lypress, inhaled glucocorticoid receptor antagonists, such as oxytocin, octreotide, oxytocin, pitressin, secretin, sincalide, terlipressin, thymopentin, thymosine, ), Triptorelin, bivalirudin, carbetocin, cyclosporine, exedine, lanreotide, luteinizing hormone-releasing hormone (LHRH) And includes any one of nafarelin, parathyroid hormone, pramlintide, T-20 (enfuvirtide), thymalfasin and chicotanide.

Further, the solvent of the chemical liquid (M) dissolves the biocompatible material. Such solvents include, but are not limited to, DI water, methanol, ethanol, chloroform dibutyl phthalate, dimethyl phthalate, ethyl lactate, glycerin And at least one of inorganic and organic solvents including glycerin, isopropyl alcohol, lactic acid, propylene glycol and the like.

For reference, in this embodiment, as shown in Table 1 below, the micro needle 1 was prepared with the composition and temperature of the chemical solution (M) sample under three conditions.

Furtherance Temperature Sample 1 CMC 7.05% + DW 92.95% 10 ℃ Sample 2 CMC 7.05% + DW 92.95% 25 ℃ Sample 3 CMC 8.2% + DW 91.8% 25 ℃

Here, CMC (carboxymethylcellulose, low viscosity; Sigma) is a thickener and DW is a purified water.

The graph of the viscosity change (CMC% -CP) according to the thickener can be obtained as shown in FIG. 4 by measuring the viscosity of the chemical liquid (M) having different CMC% among the three samples prepared under the conditions as shown in Table 1 have. As shown in FIG. 4, the viscosities of the three kinds of CMC% obtained in Table 1 and the viscosity of the coating solution, that is, the chemical solution (M), were measured.

As shown in FIG. 4, it can be seen that the viscosity change at 10 ° C at the same temperature as Sample 2 changes the viscosity from 936.54 cP to 1979 cP at point A. Also, as shown at point B in FIG. 4, it can be seen that when the temperature of the sample having CMC of 9.4% is 25 ° C and the viscosity is decreased from 4588cP to 10 ° C, the viscosity is changed to 9242cP.

5 shows a graph in which the evaporation rates of the chemical liquid M with respect to time are observed using Samples 1 and 2 of Table 1. Referring to the graph of FIG. 5, it can be seen that the evaporation rate of the chemical liquid (M) over time of the sample 1 is drastically reduced as compared with the sample 2.

FIG. 6 shows a state in which the micro-needle 1 is uniformly coated with the chemical liquid M having the conditions of Samples 1 to 3 under an optical microscope. 6 (a) is a micro needle 1 coated with the condition of Sample 1, and the coating height is 425 占 10.8 占 퐉. 6 (b), the coating height of the coated micro needle 1 under the condition of the sample 2 is 344.5. + -. 20.8 .mu.m. Referring to FIG. 6 (c) Is 307.1 占 16.4 占 퐉. That is, as shown in FIG. 6, it can be seen that the coating height of the micro needle 1 can be varied according to various conditions.

FIG. 7A shows the condition of CMC 2% + chemical solution 15% + purified water 83%, (b) CMC 4% + chemical solution 15% + purified water 81% condition, (c) CMC 6% + chemical solution 15% (D) shows the tendency of increasing the surface coating amount of the micro needle 1 according to the increase of the viscosity under the condition of CMC 8% + 15% of drug solution + 77% of purified water by optical microscope Respectively.

As shown in FIG. 7 (a), the coating height of the micro needle 1 coated with 2% CMC, 15% chemical and 83% purified water was 191.210 ± 42.480 μm, and CMC 4% + The coated height of the micro needle 1 coated with the chemical solution of 15% + purified water of 81% was 274.211 ± 27.696 탆. 7 (c), the coating height of the micro needle 1 coated with 6% CMC + 15% CMC + 79% purified water is 297.347 + 34.275 탆, and CMC 8 The coating height of the micro needle 1 coated with% + chemical 15% + purified water 77% is 349.291 ± 12.108 μm.

As shown in FIG. 7, the composition in which the surface coating of the micro needle 1 is most uniform is the composition (d), and the viscosity at this time is about 4500 to 5000 cP, which is the most excellent coating state.

Although the present invention has been described with reference to the preferred embodiments thereof, it will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit and scope of the invention as defined in the following claims. It can be understood that

1: Micro needle 2: Base
3: Tip 10: Micro needle manufacturing device
20: carrying unit 30: regulating unit
31: temperature holding member 32: cooling member
M: Solution

Claims (14)

A microneedle manufacturing apparatus for manufacturing a microneedle coated with a chemical solution,
A carrying unit carrying a drug solution for coating the micro needle; And
An adjusting unit for adjusting the temperature of the chemical solution carried on the supporting unit;
/ RTI >
Wherein the control unit controls the temperature of the chemical liquid to be maintained at a predetermined temperature by cooling the temperature of the chemical liquid.
The method according to claim 1,
Wherein the supporting unit has a container shape in which an upper portion is opened,
Wherein the adjustment unit is provided at the bottom of the carrying unit to cool the temperature of the carrying unit.
The method according to claim 1,
The adjustment unit includes:
A temperature holding member installed at a bottom of the supporting unit to maintain the temperature of the chemical liquid; And
A cooling member provided at the bottom of the carrying unit with the temperature holding member interposed therebetween to cool the carrying unit;
Wherein the micro needle manufacturing apparatus comprises:
The method of claim 3,
Wherein the temperature holding member comprises a Peltier element,
And the cooling member includes a cooling fan for cooling by the coolant.
Adjusting the temperature of the chemical liquid; And
Coating the drug solution on the surface of the micro needle by supporting the micro needle with the drug solution;
/ RTI >
Wherein the temperature adjusting step is performed by cooling the temperature of the chemical liquid.
6. The method of claim 5,
Wherein the chemical liquid adjusting step comprises:
The method comprising the steps of: cooling the drug solution carried on the carrier unit through a cooling member, and then maintaining the temperature of the drug solution at a predetermined temperature by a drug solution holding member including a Peltier element.
6. The method of claim 5,
And drying the microneedles coated with the drug solution after the chemical solution coating step.
6. The method of claim 5,
Wherein the chemical liquid is formed by mixing a biocompatible material with a solvent.
9. The method of claim 8,
The biocompatible material may be,
But are not limited to, hyaluronic acid, alginic acid, pectin, carrageenan, chondroitin (sulfate), dextran (sulfate), chitosan, polylysine, collagen, gelatin, carboxymethyl chitin ), Fibrin, agarose, pullulan polylactide, polyglycolide (PGA), polylactide-glycolide copolymer (PLGA), hyaluronic acid, alginic acid, , Chondroitin (sulfate), dextran (sulfate), chitosan, polylysine, collagen, gelatin, carboxymethyl chitin, fibrin, agarose, pullulan polyanhydride, But are not limited to, polyorthoesters, polyether esters, polycaprolactones, polyesteramides, poly (butyric acid), poly (valeric acid), polyurethanes, polyacrylates, But are not limited to, ethylene-vinyl acetate polymers, acrylic substituted cellulose acetates, non-degradable polyurethanes, polystyrenes, polyvinylchlorides, polyvinyl fluorides, poly (vinylimidazoles), chlorosulphonate polyolefins, Polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), polymethacrylate, hydroxypropylmethylcellulose (HPMC), ethylcellulose (EC), hydroxypropylcellulose (HPC), carboxymethylcellulose, cyclodextrin, A method of producing a micro needle comprising at least one selected from the group consisting of a copolymer of monomers forming such a polymer and a cellulose
9. The method of claim 8,
The chemical liquid is mixed with an additive for increasing the mechanical strength,
The additive may be selected from the group consisting of trehalose, glucose, maltose, lactose, lactulose, fructose, turanose, melitose, melitose, dextran, sorbitol, xylitol, palatinite, mannitol, poly (Glycolides), poly (lactide-co-glycolide), polyanhydride, polyorthoester, polyetherester, polycaprolactone e, but are not limited to, polyesteramide, poly (butyric acid), poly (valeric acid), polyurethanes, polyacrylates, ethylene-vinyl acetate polymers, acrylic substituted cellulose acetate, non-degradable polyurethanes, polystyrene, polyvinyl chloride, Poly (vinylimidazole), chlorosulfonate, chlorosulphonate polyolefins, polyethylene oxide, polyvinylpyrrolidone (PVP), poly (PEG), polymethacrylate, hydroxypropylmethylcellulose (HPMC), ethylcellulose (EC), hydroxypropylcellulose (HPC), carboxymethylcellulose, cyclodextrin, and monomers forming these polymers Wherein the microneedles are made of one or two or more substances selected from the group consisting of a combination of two or more substances.
9. The method of claim 8,
The drug solution is mixed with active ingredients,
The active ingredient may be a protein / peptide drug, a hormone, a hormone analogue, an enzyme, an enzyme inhibitor, a signal transduction protein or a part thereof, an antibody or a part thereof, a single chain antibody, a binding protein or a binding domain thereof, A protein, a toxin protein, a cytokine, a transcription regulator, a blood coagulation factor, and a vaccine.
12. The method of claim 11,
The protein / peptide medicament may be selected from the group consisting of insulin, IGF-1 (insulin sensitivity factor 1), growth hormone, erythropoietin, granulocyte-colony stimulating factors (G-CSFs), granulocyte / macrophage- Interferon alpha, interferon beta, interferon gamma, interleukin-1 alpha and beta, interleukin-3, interleukin-4, interleukin-6, interleukin-2, epidermal growth factors, calcitonin, adrenocorticotropic hormone ), TNF (tumor necrosis factor), atobisban, buserelin, cetrorelix, deslorelin, desmopressin, dinorpin A dynorphin A (1-13), elcatonin, eleidosin, eptifibatide, growth hormone releasing hormone-II (GHRH-II), gonadorelin, Goserelin, histrelin, leuprorelin, lypressin, octreotide, the compounds of the present invention may be selected from the group consisting of octreotide, oxytocin, pitressin, secretin, sincalide, terlipressin, thymopentin, thymosine, a triptorelin, a bivalirudin, a carbetocin, a cyclosporin, an exedine, a lanreotide, a luteinizing hormone-releasing hormone (LHRH), a nafarelin, A method for producing a micro needle comprising at least one of a hormone, pramlintide, T-20 (enfuvirtide), thymalfasin and chicotanide.
9. The method of claim 8,
The chemical solution is added with a solvent,
The solvent may be selected from the group consisting of DI water, methanol, ethanol, chloroform dibutyl phthalate, dimethyl phthalate, ethyl lactate, glycerin An organic solvent such as glycerin, isopropyl alcohol, lactic acid, propylene glycol and the like.
A microneedle manufactured by any one of claims 5 to 13.

Images